106 related articles for article (PubMed ID: 7610511)
1. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.
McCune CS; O'Donnell RW; Marquis DM; Sahasrabudhe DM
Cancer Immunol Immunother; 1990; 32(1):62-6. PubMed ID: 2289200
[TBL] [Abstract][Full Text] [Related]
2. "Pseudoprogression": more than semantics.
Dutcher JP
Cancer Immunol Immunother; 2018 Sep; 67(9):1473-1474. PubMed ID: 30022219
[No Abstract] [Full Text] [Related]
3. Reply to "Pseudoprogression": more than semantics.
Wong AS; Lee MB
Cancer Immunol Immunother; 2018 Sep; 67(9):1475. PubMed ID: 30062556
[No Abstract] [Full Text] [Related]
4. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
5. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
6. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
7. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
Schmitz-Dräger BJ; Jankevicius F; Otto T
Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
[TBL] [Abstract][Full Text] [Related]
10. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
van Herpen CM; de Mulder PH
Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and molecular markers for renal cell carcinoma.
Bui MH; Zisman A; Pantuck AJ; Han KR; Wieder J; Belldegrun AS
Expert Rev Anticancer Ther; 2001 Dec; 1(4):565-75. PubMed ID: 12113089
[TBL] [Abstract][Full Text] [Related]
12. [Guideline 'Renal cell carcinoma'].
Mulders PF; Brouwers AH; Hulsbergen-van der Kaa CA; van Lin EN; Osanto S; de Mulder PH
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):376-80. PubMed ID: 18380384
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
